Neurocrine Biosciences (NBIX) Cash from Operations Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 27.85% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 72.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.81% |
| Dec 31, 2025 | 39.52% |
| Sep 30, 2025 | 32.05% |
| Jun 30, 2025 | -9.61% |
| Mar 31, 2025 | 53.26% |
| Dec 31, 2024 | 286.50% |
| Sep 30, 2024 | 36.74% |
| Jun 30, 2024 | -14.46% |
| Mar 31, 2024 | 14.28% |
| Dec 31, 2023 | 9.33% |
| Sep 30, 2023 | 131.41% |
| Jun 30, 2023 | 14.74% |
| Mar 31, 2023 | -76.80% |
| Dec 31, 2022 | 13.62% |
| Sep 30, 2022 | 0.34% |
| Jun 30, 2022 | 29.09% |
| Mar 31, 2022 | 28.86% |
| Dec 31, 2021 | -56.35% |
| Sep 30, 2021 | -3.57% |
| Jun 30, 2021 | 71.44% |